The Takeda spinoff is developing a vaccine for acute gastroenteritis caused by norovirus infection, and raised about $140m in August 2021.

HilleVax, a US-based vaccine developer spun off by pharmaceutical firm Takeda, has filed for an initial public offering on the Nasdaq Global Select Market.

Formed as a collaboration between Takeda and venture capital firm Frazier Healthcare Partners, HilleVax is working on a vaccine for norovirus infection-triggered acute gastroenteritis.

HilleVax’s lead product candidate, HIL-214, has already undergone several clinical tests under Takeda’s auspices, but the company has transferred the open investigational new drug application for it to HilleVax, which now…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn